BRIEF published on 12/11/2025 at 11:48, 1 month 22 days ago Semperit Extends CIO Gerfried Eder's Term Until 2029 Market Position Executive Board Industrial Applications Semperit AG Gerfried Eder
PRESS RELEASE published on 12/11/2025 at 11:43, 1 month 22 days ago Semperit: CIO Gerfried Eder’s term on the Executive Board extended until 2029 Semperit AG Holding extends CIO Gerfried Eder's term on Executive Board until 2029. Eder responsible for Industrial Applications division and commercial excellence Executive Board Industrial Applications Extension Semperit AG Holding Gerfried Eder
BRIEF published on 11/17/2025 at 09:05, 2 months 15 days ago NuWays AG Recommends Buy for Semperit AG Holding Financial Performance NuWays AG Investment Recommendation EBITDA Growth Semperit AG Holding
PRESS RELEASE published on 11/17/2025 at 09:00, 2 months 15 days ago Original-Research: Semperit AG Holding (von NuWays AG): Buy NuWays AG research report on Semperit AG Holding highlights Q3 results, EBITDA growth, solid cash position, and improved end market demand positioning for sustainable growth NuWays AG Q3 Results EBITDA Growth Semperit AG Holding Research Report
BRIEF published on 11/12/2025 at 07:35, 2 months 20 days ago Semperit Maintains Positive Momentum in Q3 2025 Financial Performance Cost Savings EBITDA Growth Semperit Group Q3 2025 Results
PRESS RELEASE published on 11/12/2025 at 07:30, 2 months 20 days ago Semperit: Positive momentum continues in the third quarter of 2025 Semperit AG Holding reports positive momentum with improved EBITDA and revenue in Q3 2025. Cost savings and recovery in order situation contribute to earnings growth EBITDA Revenue Cost Savings Semperit AG Holding Q3 2025
BRIEF published on 11/05/2025 at 09:05, 2 months 27 days ago Solid Prospects for Semperit AG Holding in Q3 2025 Operational Improvements Revenue Growth Financial Forecast Semperit Q3 2025
PRESS RELEASE published on 11/05/2025 at 09:00, 2 months 27 days ago Original-Research: Semperit AG Holding (von NuWays AG): Buy Semperit AG Holding to report solid Q3 2025 results on Nov 12, with expected growth in sales and EBITDA margin. NuWays AG updates 'Buy' recommendation and sets target price at EUR 18.20 Buy Recommendation NuWays AG Semperit AG Holding Q3 2025 Results EUR 18.20 Target Price
BRIEF published on 08/15/2025 at 09:05, 5 months 18 days ago Semperit AG Holding Shows Resilience Amid Market Challenges EBITDA Guidance Semperit AG Holding Q2 Earnings SEA Segment Cyclical Recovery
PRESS RELEASE published on 08/15/2025 at 09:00, 5 months 18 days ago Original-Research: Semperit AG Holding (von NuWays AG): BUY NuWays AG Research recommends BUY rating for Semperit AG Holding due to Q2 performance and confirmation of FY25 guidance. Improved margins and strong balance sheet enhance growth prospects NuWays AG BUY Rating Research Semperit AG Holding Q2 Performance
Published on 02/02/2026 at 23:55, 7 hours 23 minutes ago 2026 Tunkillia Development Drilling Programs Begin
Published on 02/02/2026 at 23:55, 7 hours 23 minutes ago 55 North Mining Announces Winter Exploration Drill Program at Last Hope Gold Project
Published on 02/02/2026 at 23:25, 7 hours 53 minutes ago Western Announces Sale of GlassMasters Investment
Published on 02/02/2026 at 22:05, 9 hours 13 minutes ago Organto Foods to Attend Fruit Logistica 2026 in Berlin, Germany From February 4-6, 2026
Published on 02/02/2026 at 15:00, 16 hours 18 minutes ago Jericho Energy Ventures Strategically Terminates SmartKem LOI to Advance Independent Data Center Energy Infrastructure Platform
Published on 02/03/2026 at 07:00, 18 minutes ago Siltronic AG with preliminary financial figures: Targets for 2025 achieved despite challenging conditions
Published on 02/03/2026 at 07:00, 18 minutes ago Sartorius Stedim Biotech achieves considerable profitable growth in 2025 and maintains positive outlook
Published on 02/03/2026 at 07:00, 18 minutes ago Medacta Group SA: Medacta Group reports continued significant above-market revenue growth of 18.5% in constant currency in 2025
Published on 02/03/2026 at 07:00, 18 minutes ago Sartorius achieves considerable profitable growth in 2025 and maintains positive outlook
Published on 02/03/2026 at 07:00, 18 minutes ago Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Published on 02/02/2026 at 18:23, 12 hours 55 minutes ago Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:00, 13 hours 18 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 02/02/2026 at 17:35, 13 hours 43 minutes ago Disclosure of transactions in own shares from January 26 to January 30, 2026
Published on 02/02/2026 at 17:22, 13 hours 56 minutes ago Statement of transactions in own shares from January 26, 2026 to January 30, 2026
